Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department?

Department of Emergency Medicine, Singapore General Hospital, Tumasik, 00, Singapore
Resuscitation (Impact Factor: 3.96). 08/2007; 74(1):27-37. DOI: 10.1016/j.resuscitation.2006.11.010
Source: PubMed

ABSTRACT Patients in coma with suspected drug poisoning are commonly encountered in the emergency department. Benzodiazepines are one of the most commonly used drugs in self-poisoning. Flumazenil, a benzodiazepine antagonist has been suggested as a diagnostic and treatment tool in suspected poisoning of unclear cause, but caution is required due to potential side effects. No systemic review of this literature has been done on this topic.
The aim of this study is to examine if flumazenil should be used in patients with coma from suspected drug poisoning.
Randomised controlled trials were identified from the Cochrane Library, Pubmed and EMBASE. Bibliographies from included studies, known reviews and texts were searched. Content experts were contacted.
Randomised controlled trials were eligible for inclusion. Studies were included if patients who presented with altered mental state from suspected drug poisoning were treated with intravenous flumazenil as compared to placebo.
Data were extracted and methodological quality was assessed independently by two reviewers.
Seven randomised controlled trials were included. A total of 466 patients were involved. Flumazenil was found to reverse coma from suspected drug poisoning with a relative benefit of 4.45 (95% CI 2.65, 7.45). In terms of major side effects, there was no statistical difference between flumazenil and placebo (RR 2.86, 95% CI 0.12-69.32). However, in terms of minor side effects, flumazenil was associated with a higher incidence of anxiety (RR 2.84, 95% CI 1.28-6.30) and other side effects (RR 3.73, 95% CI 2.078-6.73). There was no difference in the incidence of vomiting (RR 4.28, 95% CI 0.95-19.35).
Current evidence shows that flumazenil may be effective in the reversal of coma in patients presenting to the emergency department with coma from suspected drug poisoning.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The Bayesian estimation scheme has proved widely useful in providing estimates of inexactly observable parameters and state variables of noisy linear discrete-time systems for the derivation of an optimal control policy. Controllers may be derived which are adaptive and relatively insensitive to system parameter changes. In this paper dual control schemes are developed for a class of discrete-time noisy extremum systems given by the state equations x(t+1) = ¿x(t) + Bu(t) + w(t) (1) z1 (t) = - + v1(t) (2) The optimal control policy is defined as that which minimizes ¿t=0 T-1 E {x(t+1)tx(t+1)} The control scheme is intentionally sub-optimal to reduce computation to a feasible level. The technique is to reduce Equation (2) by a series of approximations to a set of linear equations. A set of control schemes may be set up based on the Bayesian estimation approach and the set of linearized equations. An algorithm for choosing at each time interval which of the control schemes is to be used to calculate the control is developed such that it satisfies certain performance criteria. The results of extensive computer studies of one-and two-dimensional extremum systems are presented.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We bespreken twee adolescenten met een bewustzijnsdaling door onbekende oorzaak. Deze casus illustreren hoe intoxicaties zich bij adolescenten kunnen presenteren en welke klinische overwegingen zich hierbij voordoen. Patiënt 1, een 13-jarige jongen, werd door zijn vader binnengebracht.Wegens bewustzijnsdaling e.c.i. werd flumazenil toegediend, waarna hij weer bij bewustzijn kwam. Patiënt 2, een 16-jarig meisje, werd bewusteloos binnengebracht door ambulancepersoneel. Een (hetero)anamnese was niet mogelijk. Op klinische gronden werd een intoxicatie met gammahydroxyboterzuur (GHB) vermoed. Dilemma’s met betrekking tot de therapeutische benadering (intubatie en medicatie) worden besproken. Als leerpunten komen uit dit tweetal patiëntencasus naar voren: de diagnostische waarde van flumazenil bij bewustzijnsverlies e.c.i. en de benadering van mogelijke GHB-intoxicaties bij adolescenten in de acute situatie.
    Tijdschrift voor kindergeneeskunde 10/2012; 80(5). DOI:10.1007/s12456-012-0034-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both alcohol withdrawal syndrome (AWS) and benzodiazepines can cause delirium. Benzodiazepine-associated delirium can complicate AWS and prolong hospitalization. Benzodiazepine delirium can be diagnosed with flumazenil, a GABA-A receptor antagonist. By reversing the effects of benzodiazepines, flumazenil is theorized to exacerbate symptoms of AWS and precludes its use. For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events. Hospital admission records were retrospectively reviewed for patients with the diagnosis of AWS who received both benzodiazepines and flumazenil from December 2006 to June 2012 at a university-affiliated inpatient toxicology center. The day of last alcohol consumption was estimated from available blood alcohol content or subjective history. Corresponding benzodiazepine, flumazenil, and adjunctive sedative pharmacy records were reviewed, as were demographic, clinical course, and outcome data. Eighty-five patients were identified (average age 50.3 years). Alcohol concentrations were detectable for 42 patients with average 261 mg/dL (10-530 mg/dL). Eighty patients were treated with adjunctive agents for alcohol withdrawal including antipsychotics (n = 57), opioids (n = 27), clonidine (n = 35), and phenobarbital (n = 23). Average time of flumazenil administration was 4.7 days (1-11 days) after abstinence, and average dose was 0.5 mg (0.2-1 mg). At the time of flumazenil administration, delirium was described as hypoactive (n = 21), hyperactive (n = 15), mixed (n = 41), or not specified (n = 8). Response was not documented in 11 cases. Sixty-two (72.9 %) patients had significant objective improvement after receiving flumazenil. Fifty-six patients required more than one dose (average 5.6 doses). There were no major adverse events and minor adverse effects included transiently increased anxiety in two patients: 1 patient who received 0.5 mg on abstinence day 2 and another patient who received 0.2 mg flumazenil on abstinence day 11. This is the largest series diagnosing benzodiazepine delirium after AWS in patients receiving flumazenil. During the treatment of AWS, if delirium is present on day 5, a test dose of flumazenil may be considered to establish benzodiazepine delirium. With the limited data set often accompanying patients with AWS, flumazenil diagnosed benzodiazepine delirium during the treatment of AWS and improved impairments in cognition and behavior without serious or life-threatening adverse events in our patients.
    Journal of medical toxicology: official journal of the American College of Medical Toxicology 03/2014; 10(2). DOI:10.1007/s13181-014-0391-6